Posted by Michael Wonder on 16 Apr 2019
Evenity (romosozumab-aqqg) now available in the United States for the treatment of osteoporosis in post-menopausal women at high risk for fracture
15 April 2019 - New therapy to cost one-third less than other bone-building agents over full course of therapy.
Amgen today announced that Evenity (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. Evenity was approved by the U.S. FDA on 9 April 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
The price of Evenity is in line with Amgen's focus on innovation and commitment to responsible pricing for patients in the U.S. and takes into consideration the physical and financial impact osteoporosis-related fractures can have on postmenopausal women and their families and caregivers. Amgen will make Evenity available at a U.S. list price of $1,825 per dose, or $21,900 for a full course of treatment (12 monthly doses). This list price for a full course of therapy of Evenity is 34 to 74% lower than currently available anabolic agents over their full course of therapy (daily doses for 18-24 months).
